Positions
- Professor
-
Urology
糖心视频 of Medicine
Houston, TX, US
Beth and Dave Swalm Chair in Urologic Oncology Director of Urologic Oncology Director of the Multidisciplinary Bladder Cancer Program
Addresses
- 糖心视频 of Medicine Medical Center (Clinic)
-
7200 Cambridge, Suite 10B
Houston, TX, 77030
United States
Phone: (713) 798-4001
Education
- B.A. from University Of Texas At Austin
- 01/1979 - Austin, TX, United States
- M.D. from 糖心视频 Of Medicine
- 01/1984 - Houston, TX, United States
- Internship at Virginia Mason Hospital
- 01/1985 - Seattle, Washington, United States
- Residency at Virginia Mason Hospital
- 06/1986 - Seattle, Washington, United States
- General Surgery
- Residency at 糖心视频 of Medicine
- 06/1990 - Houston, Texas, United States
- Urology
- Fellowship at University Of Southern California
- 06/1992 - Los Angeles, California, United States
- Urologic Oncology
Certifications
- American Board of Urology
Professional Interests
- Urologic Oncology and Reconstructive Surgery with Interest in Minimally Invasive Surgery
Professional Statement
Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, 糖心视频 of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic.
He earned his medical degree from 糖心视频 of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer.
Dr. Lerner is author of over190 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. He is the founding co-editor-in-chief of the Bladder Cancer journal. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated genomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 26 years experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force and current co-chair of the NCI CTEP Genitourinary Steering Committee, and he has co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer for the past 7 years. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among 鈥淎merica鈥檚 Top Doctors鈥 and 鈥淏est Doctors in America.
He earned his medical degree from 糖心视频 of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer.
Dr. Lerner is author of over190 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. He is the founding co-editor-in-chief of the Bladder Cancer journal. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated genomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 26 years experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force and current co-chair of the NCI CTEP Genitourinary Steering Committee, and he has co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer for the past 7 years. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among 鈥淎merica鈥檚 Top Doctors鈥 and 鈥淏est Doctors in America.
Selected Publications
-
Levitt JM, Jian W, Lerner SP, Sonpavde G. " " Urol. Oncol.. 2013 Feb ; 31 (2) : 234-40.
Pubmed PMID: . -
Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. " " J. Urol.. 2012 Dec ; 188 (6) : 2391-7.
Pubmed PMID: . -
Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. " " Eur. Urol.. 2012 Sep ; 62 (3) : 523-33.
Pubmed PMID: . -
Jian PY, Godoy G, Coburn M, Lynch G, Ro JY, Zhai QJ, Nishino M, Lerner SP. " " Can Urol Assoc J. 2012 Apr ; 6 (2) : E77-80.
Pubmed PMID: .
Memberships
- American Association of Genitourinary Surgeons
- Member
- American Urological Association
- Member
- American Association for Cancer Research
- Member
- American Association for the Advancement of Science
- Member
- American College of Surgeons
- Fellow
- American Medical Association
- Member
- American Society of Clinical Oncology
- Member
- American Society of Gene Therapy
- Member
- American Association of Clinical Urologists
- Member
- Harris County Medical Society
- Member
- International Bladder Cancer Network
- Member
- Society of Basic Urologic Research
- Member
- Soci茅t茅 International D鈥橴rologie
- Member
- Society of Laparoendoscopic Surgeons
- Member
- South Central Section of the American Urological Association
- Member
- Society of University Urologists
- Member
- Southwest Oncology Group
- Member
- Texas Urological Society
- Member
- Texas Medical Association
- Member
Skills
- Research Interests
- Bladder Cancer Collaborative Research Program: Role of estrogen receptors and the use of selective estrogen receptor modulators (e.g., tamoxifen) for treatment of bladder cancer; novel targeted therapeutics and gene therapy for treatment of non-muscle-invasive and invasive disease; outcome of treatments for non-muscle-invasive bladder cancer and radical cystectomy and development of predictive models; genomic characterization and integrated analysis of bladder and upper tract cancers
- Clinical Interests
- Urologic oncology and urinary tract reconstruction; management of patients with bladder, prostate, testis and kidney cancer; Director, Bladder Cancer Multidisciplinary Clinical Program
- Clinical Trials
- Bladder cancer; prostate cancer; kidney cancer
to edit your profile